FDA Approves Inclisiran

FDA Approves Inclisiran

December 23, 2021

InclisiranToday the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein cholesterol (LDL-C) lowering. Inclisiran is an injection administered in the doctor's office twice a year to be used along with diet and maximally tolerated statin therapy and may reduce circulating levels of LDL-C up to 51%.

Related posts:

  1. FDA Listening Session for HoFH
  2. ICER Report on Treatments for High Cholesterol – Family Heart Foundation to Comment at Public Meeting February 5
  3. Why are FH patients paying a higher price for PCSK9 inhibitor treatment when a lower price is available, and what can we do about it?
  4. New Drug for Homozygous Familial Hypercholesterolemia Approved by the FDA

Leave a Reply